However, since the onset of AML/MDS associated with PARP inhibition was found to be almost 18 months since the first treatment,27 further studies with larger patient numbers and longer follow-up durations are needed to clarify the risk of hematologic malignancy with senaparib. The gene discussed is PARP1; the disease is myelodysplastic syndrome.